{"id":"trastuzumab-emtansine-for-injection","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Abdominal pain"},{"rate":"5-20%","effect":"Infusion-related reactions"},{"rate":"5-20%","effect":"Hypertension"},{"rate":"5-20%","effect":"Headache"},{"rate":"5-20%","effect":"Dizziness"},{"rate":"5-20%","effect":"Muscle pain"},{"rate":"5-20%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1743082","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trastuzumab emtansine is a monoclonal antibody-drug conjugate that binds to the HER2 protein on the surface of cancer cells. Once bound, it releases a toxic compound called DM1, which kills the cancer cells.","oneSentence":"Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:54.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"},{"name":"Treatment of HER2-positive breast cancer"},{"name":"Treatment of HER2-positive gastric cancer"}]},"trialDetails":[{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT06830889","phase":"PHASE3","title":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-03","conditions":"HER2-positive Breast Cancer","enrollment":1450},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT07008976","phase":"PHASE3","title":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-07","conditions":"Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT01565200","phase":"PHASE2","title":"HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2012-05","conditions":"HER-2 Positive Breast Cancer","enrollment":90},{"nctId":"NCT06718335","phase":"NA","title":"Pyrotinib in HER2-positive Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nie Jianyun","startDate":"2024-12-30","conditions":"HER2-positive Breast Cancer","enrollment":156},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT04197687","phase":"PHASE2","title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","status":"UNKNOWN","sponsor":"Academic and Community Cancer Research United","startDate":"2020-02-20","conditions":"Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7","enrollment":480},{"nctId":"NCT05755048","phase":"PHASE3","title":"FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2023-03-28","conditions":"Breast Cancer","enrollment":314},{"nctId":"NCT04924699","phase":"PHASE2, PHASE3","title":"A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shanghai Miracogen Inc.","startDate":"2021-06-30","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":350},{"nctId":"NCT05560308","phase":"NA","title":"Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09-30","conditions":"HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy","enrollment":50},{"nctId":"NCT04296942","phase":"PHASE1","title":"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-04","conditions":"Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer","enrollment":1},{"nctId":"NCT04185649","phase":"PHASE3","title":"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Bio-Thera Solutions","startDate":"2018-07-01","conditions":"HER2-positive Advanced Breast Cancer","enrollment":410},{"nctId":"NCT03203616","phase":"PHASE2","title":"Kadcyla In pAtients With bRAin Metastasis","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2018-02-23","conditions":"Metastatic HER2-positive Breast Cancer With Brain Metastasis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trastuzumab Emtansine for Injection","genericName":"Trastuzumab Emtansine for Injection","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them. Used for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive breast cancer, Treatment of HER2-positive gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}